AGNG news

Global X Aging Population · Healthcare

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Quartz · 28 Oct 2026, 16:16 UTC
Best-selling drugs 2026: 7 of the top 10 by 2025 sales
13.3% of AGNG
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
10.3% of AGNG
Yahoo! Finance · 28 Oct 2026, 07:29 UTC
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
9.6% of AGNG
Benzinga · 28 Oct 2026, 19:32 UTC
Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings - Amazon.com (NASDAQ:AMZN), Intel (NASDAQ:INTC
6.0% of AGNG
Where to buy AGNG
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 15:55 UTC
Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha
6.6% of AGNG
24/7 Wall St. · 28 Oct 2026, 12:14 UTC
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
6.6% of AGNG
Where to buy AGNG
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Benzinga · 29 Oct 2026, 03:07 UTC
Eli Lilly Shares Rise 1.89% After Hours - Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
3.6% of AGNG
www.theepochtimes.com · 28 Oct 2026, 00:00 UTC
Judge Declines to Block Eli Lilly Weight-Loss Drug Ads in Dispute With Novo Nordisk
7.4% of AGNG
Yahoo! Finance · 27 Oct 2026, 13:47 UTC
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
9.5% of AGNG
Seeking Alpha · 27 Oct 2026, 22:08 UTC
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) | Seeking Alpha
7.4% of AGNG
24/7 Wall St. · 28 Oct 2026, 19:24 UTC
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
3.6% of AGNG
Quartz · 28 Oct 2026, 17:20 UTC
Lilly's retatrutide more than doubled Ozempic weight loss in trial
3.8% of AGNG
Seeking Alpha · 28 Oct 2026, 18:55 UTC
Roche: Valuation Leaves Limited Upside (OTCMKTS:RHHBF) | Seeking Alpha
3.2% of AGNG
Seeking Alpha · 28 Oct 2026, 19:02 UTC
Ventas outlines $3.87-$3.90 2026 normalized FFO per share outlook as SHOP investment closes reach $5.2B (NYSE:VTR) | Seeking Alpha
3.1% of AGNG
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Ventas, Inc. (VTR) Q3 2026 Earnings Call Transcript | Seeking Alpha
3.1% of AGNG
Benzinga · 28 Oct 2026, 13:25 UTC
Eli Lilly Says Retatrutide Delivers More Than Double Ozempic's Weight Loss in Late-Stage Diabetes Trial -
3.6% of AGNG
TheStreet · 28 Oct 2026, 19:33 UTC
Breakthrough cancer vaccine catches Wall Street's attention
3.0% of AGNG
Quartz · 27 Oct 2026, 11:29 UTC
Judge rejects Novo Nordisk bid to block Eli Lilly weight-loss ads
7.4% of AGNG
Market Screener · 28 Oct 2026, 12:07 UTC
Eli Lilly And Company Announces Positive Topline Results From TRANSCEND-T2D-2 Phase 3 Trial Of Retatrutide In Adults With Type 2 Diabetes
3.6% of AGNG
Benzinga · 27 Oct 2026, 10:51 UTC
Novo Nordisk Loses Court Bid Against Eli Lilly's Weight-Loss Drug Ads -- Judge Says Sales Impact Was Negli
7.4% of AGNG

AGNG news

Where to buy AGNG

Where to buy AGNG